NPPA asks drug makers to furnish prices of 56 formulations

  • News
  • April 15, 2016

New Delhi

In an effort to fix the ceiling prices of 56 drug formulations, including those for epilepsy, diabetes and heart diseases, the government has given drug makers and marketing firms a week to furnish their prices-to-retailer and MAT for August 2015. The formulations also includes those targeting bipolar disorder, dietary supplements, anticoagulants, HIV/AIDS, drug price regulator National Pharmaceutical Pricing Authority (NPPA) said in a statement. “All the concerned manufacturers/ marketing companies are requested to furnish the price-to-retailer and moving annual turnover (MAT) in value terms for the month of August 2015, with in seven days…” it said in a memorandum dated April 4. The information is required so that NPPA is able to fix the ceiling prices in a transparent manner, it added. At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than one percent. Besides, the government regulates prices of all other medicines and companies are allowed to hike prices of such drugs by only up to 10 percent in a year. The government had notified DPCO, 2013, which covers 680 formulations, with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs. Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs.

  • Related Posts

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

    • News
    • May 27, 2025
    • 281 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

    Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

    Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

    Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.